[an error occurred while processing this directive]
Particle Sciences - Technical Brief: 2011: Volume 4
Pharmacology is the branch of medicine and biology concerned with the study of the interactions that occur between a living organism and chemicals that affect biochemical functions. In the field of pharmacology, potency is a measure of drug activity expressed in terms of the amount required to produce an effect of given intensity. A highly potent drug evokes a larger response at low concentrations, while a drug of lower potency evokes a smaller response at similar concentrations.
Occupational health professionals in the pharmaceutical industry have recognized the potential for occupational disease caused by overexposure to active pharmaceutical ingredients (APIs).1 Compounds that are routinely handled in the biotechnology, pharmaceutical and medical device industries (from hereon called pharmaceutical industry) are unique in that they are designed to have an effect on the human body. Environmental, health and safety professionals in the industry have responded to this risk by developing and implementing comprehensive programs for the anticipation, recognition, evaluation, and control of exposure to APIs. This is achieved by ensuring that employees are protected from exposure to potent APIs. The purpose of this technical brief is to provide an overview of the design and implementation of an effective and economical potent compound safety precautions for the industry.
The design and implementation of an effective potent compound safety program should follow the same basic process as traditional industrial hygiene programs – hazards should be anticipated, activities with drug exposure potential should be recognized and evaluated, and finally these exposures must be controlled. A comprehensive potent compound safety program is active at all stages of product development including research, discovery, pre-clinical development, pre-formulation, initial test batches, pilot plant, scale-up and production. Prior to the introduction of new APIs into the workplace, a thorough literature search on the specific or similar compounds should be conducted. While this may seem like a simple task, it often becomes challenging to find relevant hazard information for new discovery compounds. However at this point, the primary focus should be to identify adequate information to allow preliminary classification or categorization of the compound into a control banding strategy such as those proposed by Naumann (et al., 1996)1. With a few minor revisions, this categorization scheme has been widely accepted across the pharmaceutical industry. The most common modification to the scheme described by Naumann and his colleagues is in the number of bands individual companies utilize for their compounds. Some companies use a four others use a five band system (Tables 1 and 2, respectively).
A potent compound exposure control band provides an array of safety requirements for a specific category and a source of information to determine appropriate handling practices, industrial hygiene targets for air monitoring, and a starting point for final potent compound categorization by an occupational toxicologist. These bands are a concentration range of potent compounds where personnel exposure should be controlled. Naumann, et al (1996)1 discuss the basis for establishing occupational exposure levels (OELs) during the various stages of drug development as well as the criteria evaluated in determining occupational exposure bands (OEB). Toxicologists are frequently required to exercise professional judgment to properly complete a potent compound categorization.
Once a relevant dose has been determined, an estimated OEL (contaminant concentration in a given volume of air) can be calculated using the methodologies such as those presented by Sargent (1988)2. After the potential hazards of the API have been identified and an estimated OEL has been calculated, the occupational health professional should identify the potential risk factors associated with its use.
These risk factors include:
In addition to routine laboratory and manufacturing processes, the environmental, health and safety professional should have an understanding of potential exposure situations during non-routine activities, such as emergency repair activities.
OEBs that are utilized in discovery and early development are initially assigned based on:
These bands are ranges of airborne concentrations of substances as 8-hour time-weighted averages (TWAs).
In the initial exposure evaluation process, high priority activities are those where APIs are handled in powder form, such as weighing of powders in laboratories, dispensing, blending, dry granulation, and compression activities. Once the product is either in finished solid dosage or liquid form, the exposure risk is significantly reduced.
Monitoring methods for the APIs are then needed to establish the airborne and surface concentration of APIs. Alternatively these evaluations may be performed using a surrogate powder such as Sodium Naproxen.
Employee exposure to potent compounds can be through:
The primary focus of a comprehensive potent compound safety program is to ensure employee safety through effective process containment. Containment is the design and implementation of engineering controls and personal protective equipment (PPE) for use with manufacturing, pilot plant and laboratory operations with the goal to minimize the emission of substances into the work environment limiting potential employee exposure. One example is the use of an isolator (Figure 1). The pressure within the isolator is negative with respect to the environment. This minimizes the contamination potential of the potent compound being manipulated in the isolator. Suggested activities for a successful implementation of a containment program are:
The activity to be contained needs to be studied and documented in detail. The goal is to control air and surface contamination. When handling highly potent compounds (i.e., OELs less than 1 µg/m3) containment must be provided during all laboratory procedures or steps in the manufacturing process. The entire process must be considered including the potent chemical compounds that will be handled, the equipment used and the hazards of those chemicals. Approaches can include modification of the engineering controls and the employee interface. The engineering controls need to be ergonomically designed and user friendly or there will be resistance to their use. Minimize the employee interface in a process and exposure will also be minimized. In addition to engineering, administrative controls such as proper potent compound safety training is paramount and if needed, product-specific medical surveillance may be implemented.
Design and implementation of an effective potent compound safety program requires that all elements be considered. Failure to adequately anticipate, recognize, evaluate and control exposures to potent compounds can result in costly program missteps, delayed drug development schedules, or potentially hazardous exposures to workers. To be successful, a comprehensive potent compound safety program will have contributions from safety, engineering, toxicology, industrial hygiene, and operations.
The authors thank Dr. Joe Nieusma and Dean Calhoun CIH of Affygility Solutions for the use of their previously published materials in this Technical Brief.
Particle Sciences is a leading integrated provider of formulation and analytic services and both standard and nanotechnology approaches to drug development and delivery.
3894 Courtney Street, Suite 180
Bethlehem, PA 18017